View Clinical Trial (Medical Research Study)
Longitudinal Study of the Porphyrias
| City: |
|
Charlotte |
| State: |
|
North Carolina |
| Zip Code: |
|
28203 |
| Conditions: |
|
Acute Porphyrias - Cutaneous Porphyrias |
| Purpose: |
|
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation
of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and
mortality in people with these disorders.
|
| Study Summary: |
|
The porphyrias are a group of rare metabolic diseases that may present in childhood or adult
life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most
common manifestations are related to accumulation of intermediates in the pathway and
usually occur as acute neurological attacks, or cutaneous photosensitivity. Multiple
mutations have been identified in each of the porphyrias. The risk of disability or death
from these disorders is significant, in part because diagnosis is often delayed due to lack
of adoption of diagnostic testing in clinical practice. Moreover, the natural history of
these disorders is not well described and it is not known what determines differences in
outcomes. New therapies are needed. For existing therapies, high-quality evidence on short
and long term efficacy and safety is generally lacking. Therefore, the purpose of this
long-term follow-up study of a large group of patients with the various porphyrias is to
provide a better understanding of the natural history of these disorders, as affected by
available therapies, and to aid in developing new forms of treatment.
The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a
Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes
and currently has funded 19 rare diseases clinical research consortia and one Data
Management and Coordinating Center. The Porphyrias Consortium was created as part of the
RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the
academic institutions listed in the participating institutions table. All Centers in the
Porphyrias Consortium are participating in the Longitudinal Study of the Porphyrias.
Additional centers may be added if funding is available.
The initial objective of this protocol is to assemble a well-documented group of patients
with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic
studies. The long-term objective is to conduct a longitudinal investigation of the natural
history, complications, and therapeutic outcomes in people with acute and cutaneous
porphyria.
|
| Criteria: |
|
Inclusion Criteria:
- Individuals with a documented diagnosis of a porphyria.
- For each type of porphyria, the inclusion criteria are based on
- clinical features;
- biochemical findings, as documented by laboratory reports (or copies) of
porphyria-specific testing performed after 1980 (Absolute values are preferred
for diagnostic biochemical thresholds. Fold increases in comparison to an upper
(or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated
by considerable variation between laboratories in normal limits. Equivocal
biochemical measurements may require confirmation by a consortium reference
laboratory;)
- molecular findings documenting the identification of a mutation in a
porphyria-related gene.
- In addition, an individual or a parent or guardian must be willing to give written
informed consent or assent, as appropriate.
- Provision is made for enrolling relatives who may not have symptoms but have
biochemical or molecular documentation of a porphyria, or in the case of recessive
disorders carry a disease-related mutation.
Exclusion Criteria:
- Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other
diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone
marrow diseases;
- Patients with a prior diagnosis of porphyria that cannot be documented by review of
existing medical records or repeat biochemical or DNA testing.
|
| NCT ID: |
|
NCT01561157 |
| Primary Contact: |
|
Principal Investigator
Robert J Desnick, MD, PhD
Mount Sinai School of Medicine
Dana O Doheny, MS, CGC
Phone: 212-659-6779
Email: dana.doheny@mssm.edu
|
| Backup Contact: |
|
Email: robert.desnick@mssm.edu
Robert J Desnick, MD, PhD
Phone: 212-659-6700
|
| Location Contact: |
|
Charlotte, North Carolina 28203
United States
Herbert L. Bonkovsky, MD
Phone: 704-355-9645
Email: Herbert.Bonkovsky@carolinashealthcare.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|